Recognise renal amyloid and MGRS, prove the deposited protein or lesion, and secure rapid nephrology–haematology treatment of the pathogenic clone.
Renal amyloid and MGRS overlap but are not interchangeable. AL amyloid is one MGRS lesion when produced by a small clone, while MGRS also includes monoclonal immunoglobulin deposition disease, proliferative glomerulonephritis with monoclonal deposits, light-chain proximal tubulopathy, immunotactoid disease and complement-associated patterns linked to a clone. Lesion identification, not paraprotein size, establishes renal significance.
The clinical range spans asymptomatic proteinuria to nephrotic oedema, Fanconi syndrome and rapidly progressive kidney dysfunction. Extrarenal clues include restrictive cardiomyopathy, orthostatic hypotension, peripheral or autonomic neuropathy, macroglossia, periorbital purpura, hepatomegaly and unexplained weight loss. Their absence does not exclude renal-limited monoclonal injury.
A plasma-cell or B-cell clone produces misfolded immunoglobulin light chains that form amyloid fibrils, even when the clonal burden is below conventional malignancy criteria.
Persistent inflammatory disease can generate AA amyloid, while transthyretin and hereditary precursor proteins produce other systemic forms requiring different diagnostic and treatment pathways.
Small monoclonal clones can cause immunoglobulin deposition disease, proliferative glomerulonephritis, light-chain proximal tubulopathy or complement-associated lesions without forming amyloid fibrils.
A clonal, inflammatory or inherited source produces a precursor protein prone to misfolding, aggregation or tissue-specific immunoglobulin deposition.
Amyloid fibrils or other monoclonal deposits disrupt renal filtration, commonly producing albumin-predominant proteinuria, nephrotic syndrome and progressive kidney impairment.
Selected monoclonal proteins injure proximal tubules, producing Fanconi features such as glycosuria, phosphate wasting, acidosis or hypouricaemia rather than a purely nephrotic phenotype.
Persistent amyloid or monoclonal injury can worsen kidney function, while systemic disease may also affect cardiac, neurological, hepatic and autonomic function.
Heavy albuminuria, oedema and low albumin may occur with relatively bland urine sediment and initially preserved filtration.
Breathlessness, syncope, raised biomarkers, low-voltage ECG or increased ventricular wall thickness may indicate high-risk cardiac involvement.
Glycosuria without marked hyperglycaemia, phosphate wasting, acidosis or hypouricaemia can reveal light-chain proximal tubulopathy.
Abrupt acute kidney injury, hypercalcaemia, anaemia, bone pain or infection requires expedited haematology and nephrology assessment.
Purpura, macroglossia, neuropathy, autonomic symptoms, hepatomegaly or unexplained weight loss should broaden organ staging.
Longstanding diabetes with typical microvascular disease and gradual albuminuria supports diabetic nephropathy; paraprotein, systemic deposition clues or atypical progression should prompt biopsy-led reassessment.
Both may produce bland nephrotic urine, but anti-PLA2R testing and subepithelial immune deposits differ from Congo-red-positive or monotypic deposits requiring precise protein typing.
Abrupt severe AKI with a large light-chain burden and relatively low albumin fraction suggests distal tubular casts rather than glomerular amyloid, although lesions can coexist.
Minimal change disease and FSGS can cause heavy proteinuria without characteristic systemic deposits; electron microscopy, immunofluorescence and Congo-red assessment establish the lesion.
Severe albumin loss promotes generalised oedema, venous thrombosis and infection, while autonomic or cardiac amyloid can make fluid removal poorly tolerated.
Continuing glomerular, tubular or vascular deposition can lead to irreversible chronic kidney disease and a need for kidney replacement therapy.
Myocardial infiltration and restrictive physiology can cause arrhythmia, syncope, heart failure and narrow haemodynamic tolerance, strongly influencing renal and clonal treatment.
Light-chain proximal tubulopathy may cause phosphate, bicarbonate, glucose, urate and potassium wasting, resulting in acidosis, weakness and defective bone mineralisation.
The kidney lesion creates treatment significance even when the clone would otherwise be labelled MGUS.
Congo red establishes fibrils, not their precursor; treating hereditary or AA amyloid as AL can cause serious harm.
Serum free light chains and serum plus urine immunofixation outperform electrophoresis used alone.
Restrictive physiology and autonomic dysfunction make fluid management and chemotherapy tolerance unusually narrow.
A rapid clonal response is encouraging, but deposited material and structural injury resolve slowly or incompletely.
Dismissing a small paraprotein as MGUS before renal pathology has been explained.
Calling Congo-red-positive tissue AL amyloid without definitive protein typing.
Using normal serum electrophoresis to exclude a light-chain disorder.
Interpreting free-light-chain concentrations without allowing for impaired renal clearance.
Giving aggressive diuresis to a patient with amyloid autonomic hypotension and restrictive cardiac filling.
Applying a myeloma chemotherapy regimen without lesion-specific multidisciplinary agreement and renal adjustment.
Your practice draft is saved in this browser.
A patient has only a small plasma-cell clone but kidney biopsy shows monoclonal immunoglobulin deposition causing progressive CKD. Which concept best describes this?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Cardiac amyloid, autonomic hypotension, neuropathy, cytopenia, infection and renal impairment alter tolerability. Check live NICE access, SmPCs, antiviral or antimicrobial prophylaxis and tumour-lysis planning before treatment.
Daily weight alone cannot distinguish safe decongestion from intravascular depletion. Monitor orthostasis, creatinine, sodium, potassium and magnesium; combine agents only through an agreed plan, especially with restrictive cardiomyopathy.